Cancer Prevention pp 91-100
Prevention and Early Detection of Ovarian Cancer: Mission Impossible?
Epithelial ovarian cancer is neither a common nor a rare disease. In the United States, the prevalence of ovarian cancer in postmenopausal women (1 in 2,500) significantly affects strategies for prevention and detection. If chemoprevention for ovarian cancer were provided to all women over the age of 50, side effects would have to be minimal in order to achieve an acceptable ratio of benefit to risk. This ratio might be improved by identifying subsets of individuals at increased risk or by bundling prevention of ovarian cancer with treatment for other more prevalent conditions. Approximately 10% of ovarian cancers are familial and relate to mutations of BRCA1, BRCA2, and mismatch repair genes. More subtle genetic factors are being sought in women with apparently sporadic disease. Use of oral contraceptive agents for as long as 5 years decreases the risk of ovarian cancer in later life by 50%. In one study, fenretinide (4- HPR) delayed development of ovarian cancer in women at increased risk of developing breast and ovarian cancer. Accrual to confirmatory studies has been prohibitively slow and prophylactic oophorectomy is recommended for women at increased genetic risk. Vaccines may have a role for prevention of several different cancers. Breast and ovarian cancers express mucins that could serve as targets for vaccines to prevent both cancers. Early detection of ovarian cancer requires a strategy with high sensitivity (>75% for stage I disease) and very high specificity (>99.6%) to achieve a positive predictive value of 10%. Transvaginal sonography (TVS) has achieved these values in some studies, but is limited by the cost of annual screening in a general population. Two-stage strategies that incorporate both serum markers and TVS promise to be more cost-effective. An algorithm has been developed that calculates risk of ovarian cancer based on serial CA125 values and refers patients at highest risks for TVS. Use of the algorithm is currently being evaluated in a trial with 200,000 women in the United Kingdom that will critically test the ability of a two-stage screening strategy to improve survival in ovarian cancer. Whatever the outcome, additional serum markers will be required to detect all patients in an initial phase of screening. More than 30 serum markers have been evaluated alone and in combination with CA125. Recent candidates include: HE4, mesothelin, M-CSF, osteopontin, kallikrein(s) and soluble EGF receptor. Proteomic approaches have been used to define a distinctive pattern of peaks on mass spectroscopy or to identify a limited number of critical markers that can be assayed by more conventional methods. Several groups are placing known markers on multiplex platforms to permit simultaneous assay of multiple markers with very small volumes of serum. Mathematical techniques are being developed to analyze combinations of marker levels to improve sensitivity and specificity. In the future, serum markers should improve the sensitivity of detecting recurrent disease as well as facilitate earlier detection of ovarian cancer.
Unable to display preview. Download preview PDF.
- Barnes MN, Chhieng DF, Dreher M, Jones JL, Grizzle WE, Jones L, Talley L, Partridge EE (2005) Feasibility of performing chemoprevention trials in women at elevated risk of ovarian carcinoma: initial examination of celecoxib as a chemopreventive agent. Gynecol Oncol 98:376–382PubMedCrossRefGoogle Scholar
- Baron AT, Boardman CH, Lafky JM, Rademaker A, Liu D, Fishman DA, Podratz KC, Maihle NJ (2005) Soluble epidermal growth factor receptor (sEGFR) [corrected] and cancer antigen 125 (CA125) as screening and diagnostic tests for epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev 14:306–318PubMedCrossRefGoogle Scholar
- Berchuck A, Schildkraut JM, Wenham RM, Claingaert B, Ali S, Henriott A, Halabi S, Rodriguez G, Gertig D, Purdie DM, Keleman L, Spurdle AB, Marks J, Chenevix-Trench G (2004) Progesterone receptor promoter +331A polymorphism is associated with a reduced risk of endometrioid and clear cell ovarian cancers. Cancer Epidemiol Biomarkers Prev 13:2141–2147PubMedGoogle Scholar
- Berek JS, Bast RC Jr (2006) Ovarian cancer. In: Kufe DW, Bast RC Jr, Hait W, Hong WK, Pollock RE, Weichselbaum RR, Holland JF, Frei E III (eds) Holland-Frei Cancer Medicine, 7th edn. Decker, Hamilton, Ontario, pp 1543–1568Google Scholar
- Finn O (2004) History of tumour vaccines and novel approaches for preventive cancer vaccines. Dev Biol (Basel) 116:3–12Google Scholar
- Jacobs IJ, Kohler MF, Wiseman R, Marks J, Whitaker R, Kerns BJM, Humphrey P, Berchuck A, Ponder BAJ, Bast RC Jr (1992) Clonal origin of epithelial ovarian cancer: Analysis by loss of heterozygosity, p53 mutation and X chromosome inactivation. J Natl Cancer Inst 84:1793–1798PubMedCrossRefGoogle Scholar
- Jacobs I, Stabile I, Bridges J, Kemsley P, Reynolds C, Grudzinskas J, Oram D (1999) Multimodal approach to screening for ovarian cancer. Lancet 1:268–271Google Scholar
- Leitao M, Pothuri B, Viale A, Olshen A, Boyd J (2003) Gene expression profiling of ovarian cystic epithelium reveals a quasi-neoplastic phenotype. Gynecol Oncol 88:196Google Scholar
- Lu KH, Patterson AP, Wang L, Marquez RT, Atkinson EN, Baggerly KA, Ramoth L, Rosen DG, Liu J, Hellstrom I, Smith D, Hartmann L, Fishman D, Berchuck A, Schmandt R, Whitaker R, Gershenson DM, Mills GB, Bast RC Jr (2004) Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis. Clinical Cancer Res 10:3291–3300CrossRefGoogle Scholar
- Marquez RT, Baggerly KA, Patterson AP, Liu J, Broaddus R, Frumovitz M, Atkinson EN, Smith D, Hartmann L, Fishman D, Berchuck A, Whitaker R, Gershenson D, Mills GB, Bast RC Jr, Lu K (2005) Patterns of gene expression in different histotypes of epithelial ovarian cancer correlate with those in normal fallopian tube, endometrium and colon. Clin Cancer Res 11:6116–6126PubMedCrossRefGoogle Scholar
- Mills GB, Lu Y, Fang X, Wang H, Eder A, Mao M, Swaby R, Cheng KW, Stokoe D, Siminovitch K, Jaffe R, Gray J (2001) The role of genetic abnormalities of PTEN and the phosphotidylinositol 3-kinase pathway in breast and ovarian tumorigenesis, prognosis and therapy. Semin Oncol 28:125–141PubMedCrossRefGoogle Scholar
- Narod SA, Dube MP, Klijn J, Lubinski J, Lynch HT, Ghadirian P, Provencher D, Heimdal K, Moller P, Robson M, Offit K, Isaacs C, Weber B, Friedman E, Gershoni-Baruch R, Rennert G, Pasini B, Wagner T, Daly M, Garber JE, Neuhausen SL, Ainsworth P, Olsson H, Evans G, Osborn M, Couch F, Foulkes WD, Warner E, Kim-Sing C, Olopade O, Tung N, Saal HM, Weitzel J, Merajver S, Gauthier-Villars M, Jernstrom H, Sun P, Brunet JS (2002) Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst 23:1773–1779Google Scholar
- Pothuri B, Leitao M, Barakat R, Akram M, Bogomolniy F, Olvera N, Lin O, Soslow R, Robson M, Offit K, Boyd J (2004) Analysis of ovarian carcinoma histogenesis. SGO Abstract #616Google Scholar
- Skates SJ, Horick N, Yu Y, Xu F-J, Berchuck A, Havrilesky L, de Bruijn HW, van der Zee AGJ, Woolas RP, Jacobs IJ, Zhang Z, Bast RC Jr (2004) Pre-operative sensitivity and specificity for early stage ovarian cancer when combining CA 125, CA 15.3, CA 72.4 and M-CSF using mixtures of multivariate normal distributions. J Clin Oncol 22:4059–4066PubMedCrossRefGoogle Scholar
- Solomon SD, McMurray JJ, Pfeffer MA, Wittes J, Fowler R, Finn P, Anderson WF, Zauber A, Hawk E, Bertagnolli M (2005) Adenoma Prevention with Celecoxib (APC) Study investigators. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 352:1071–1080PubMedCrossRefGoogle Scholar
- Zhang Z, Bast RC Jr, Yu Y, Li Jinong, Sokoll LJ, Rai A, Rosenzweig JM, Cameron B, Meng X-Y, Berchuck A, van Haaften-Day C, Hacker NF, de Bruijn HWA, van der Zee A, Jacobs IJ, Fung ET, Chan D (2004) A panel of serum biomarkers identified through proteomic profiling for the detection of early stage ovarian cancer. Cancer Res 64:5882–5890PubMedCrossRefGoogle Scholar
- Zhang Z, Xu F-J, Yu Y, Berchuck A, Havrilesky L, de Bruijn HW, van der Zee A, Woolas RP, Jacobs IJ, Skates S, Bast RC Jr (2006) Detection of Stage I epithelial ovarian cancer using an artificial neural network derived composite index of multiple serum markers. Gynecol Oncol, in revisionGoogle Scholar